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We identifi ed 21 rotaviruses in 129 patients with diar-
rhea in a Brazilian city with high rotavirus vaccine coverage. 
All rotaviruses were genotype P[4]G2 with 1 mixed infection 
with P[NT]G9. Although virus predominance could have oc-
curred randomly, the vaccine may be less protective against 
P[4]G2. Prospective surveillance is urgently needed.
Rotavirus causes severe diarrhea, illness, and death worldwide (1). Infection rates with rotavirus remain 
high despite improved sanitation, and vaccination is likely 
to be the best control strategy (2,3). Several candidate vac-
cines are being developed, 2 are already licensed (4,5) and 
at least 5 are being evaluated (2,6). The 2 licensed rotavirus 
vaccines are designed to provide protection against rotavi-
rus gastroenteritis caused by the most common worldwide 
circulating rotavirus serotypes (2). These include G types 
G1, G2, G3, and G4 and P types P[4] and P[8] (on the basis 
of variability in the outer capsid proteins VP7 and VP4, 
respectively).
One of the currently licensed vaccines (Rotarix; Glax-
oSmithKline, Rixensart, Belgium), a live, attenuated, hu-
man monovalent rotavirus P[8]G1 vaccine, was highly 
effi cacious for preventing severe rotavirus gastroenteritis 
in phase III effi cacy studies in Latin America and Europe. 
These studies included Brazil, where the main circulating 
rotavirus genotypes were P[8]G1 and P[8]G9 (5). Brazil 
therefore took the unprecedented step of introducing this 
vaccine into its national Expanded Program for Immu-
nization in March 2006 and provided 2 free doses to all 
children <3 months of age. Vaccination coverage among 
eligible age cohorts has increased and reached 51% in Ser-
gipe (www.datasus.gov.br) in northeastern Brazil. Howev-
er, this vaccine appears less effective in preventing severe 
rotavirus gastroenteritis caused by P[4]G2 strains (5), and 
immunologic pressure exerted by the vaccine may cause 
emergence of rotavirus genotypes that are not controlled by 
the vaccine. This possibility could change the pattern and 
distribution of the most prevalent rotavirus strains in the 
vaccinated population.
Because this is an unprecedented epidemiologic situ-
ation, we monitored the effect the vaccine might have on 
predominant genotypes. We describe rotavirus genotypes 
recovered from children with acute diarrhea in Aracaju, 
Sergipe, Brazil, after the widespread introduction of the 
vaccine.
The Study
Children with acute diarrhea who came to 2 pub-
lic hospitals (Joao Alves Filho and Municipal da Zona 
Norte) and 3 health centers that provided health services 
to a population (Santa Maria) in Aracaju, Brazil, were en-
rolled from November 2006 to February 2007. Children 
who came to the hospitals were enrolled consecutively on 
specifi c days of the week by study health workers, and 
children who came to the health centers were visited at 
home after we checked the daily attendance lists of the 
centers. Acute diarrhea was defi ned as any episode <14 
days duration with >3 watery stools per day. Background 
and clinical information were collected after obtaining 
parental consent, and stool samples were stored frozen 
in duplicate at –80°C until analyzed in Liverpool, UK. 
Information on rotavirus vaccination was obtained from 
parents and cross-checked against vaccination record 
cards. A child was considered vaccinated if 2 doses of the 
vaccine had been recorded on the vaccination card. Rota-
virus detection, genotyping, electropherotyping, isolation 
of strains in cell culture, and sequencing were performed 
as described (7). Severity of diarrhea episodes was classi-
fi ed according to a modifi ed Vesikari score (8). Data were 
analyzed by using descriptive statistics in Epi-Info 2002 
(Centers for Disease Control and Prevention, Atlanta, GA, 
USA). The study protocol was reviewed and approved by 
the Ethics Committees of the Liverpool School of Tropi-
cal Medicine and the Federal University of Sergipe.
A total of 129 patients with a median age of 12 months 
(range 1 month–12 years) were enrolled. Of these, 63 
(49%) were <1 year of age, 39 (30%) were 1–2 years of 
age, and 27 (21%) were >2 years of age. A total of 21 chil-
dren (16%) were positive for rotavirus by ELISA. Of these 
children, 20 were identifi ed among 89 children enrolled in 
the hospital and 1 was identifi ed among 40 children en-
rolled in the health centers (p = 0.002). Forty-eight children 
(37%) had received the rotavirus vaccine. The frequency of 
rotavirus infection by vaccination status and age is shown 
in the Table. Among children <1 year of age, 3 (7%) of the 
44 vaccinated children were infected with rotavirus com-
pared with 5 (26%) of 19 children who did not receive the 
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vaccine (p<0.05). Among children 1–2 years of age, 4 had 
received the vaccine and 1 (25%) of them was infected with 
rotavirus compared with 8 (23%) of the 35 children who 
did not receive the vaccine (p not signifi cant).
The median (range) diarrhea severity scores of children 
with and without rotavirus infection were 12.9 (10–15.8) 
and 9.4 (5.3–13.5), respectively (p<0.001). Although num-
bers are small, vaccinated children had a median (range) 
diarrhea severity scores of 12.5 (7–15) if they were infected 
with rotavirus and 7 (3–17) if they were not infected. Simi-
larly, the median (range) severity scores for unvaccinated 
children were 13 (8–15) and 11 (4–14) for children with 
and without rotavirus infections, respectively (p not signifi -
cant).
All 21 rotavirus infections were with genotype P[4]G2. 
One child had a mixed infection with P[4]G2 and P[NT]G9. 
Nineteen specimens had short electropherotype strains, 1 
was positive but with an undefi ned pattern, and 1 had insuf-
fi cient RNA to produce a pattern.
Conclusions
Sergipe has achieved relatively high rotavirus vaccine 
coverage (54%) since introduction of the vaccine in 2006, 
with 48,165 doses provided in Aracaju. The vaccine was 
well received by the local population, and as new eligible 
children continue to be vaccinated, it is likely that vaccina-
tion levels will reach the high coverage currently attained 
for oral polio vaccine (100%) (http://tabnet.datasus.gov.
br/cgi/tabcgi.exe?idb2005/f13.def).
To our knowledge, this is the fi rst report from Brazil 
of 1 rotavirus genotype predominating in a population after 
introduction of a vaccine. The P[4]G2 strain is a genotype 
for which effectiveness of the vaccine appears to be lower. 
This genotype has been previously reported in Brazil but 
represents only 6.1% of all the genotypes published since 
2000. The proportions of strains with P[4]G2 has ranged 
from 0% to 27% in various studies, and no study reported 
that this was the predominant strain. Our fi nding of 100% 
prevalence of this genotype is unusual. Limited evidence 
of the effectiveness of Rotarix vaccine against the P[4]G2 
strain has been reported (9,10) because the VP4 and VP7 
proteins are not found in the P[8]G1 strain that is included 
in this vaccine.
Although our numbers are small, a lower proportion 
of vaccinated children had rotavirus-associated diarrhea, 
which likely refl ects the protective effect of the vaccine. 
Four children were infected despite having been vaccinated 
and their infections were as severe as those in children who 
had not received the vaccine. This fi nding confi rms that the 
vaccine does not afford complete protection against infec-
tion. Although predominance of the P[4]G2 strain in this 
population could be due to random preponderance of this 
genotype and is unrelated to vaccine use, this epidemiolog-
ic fi nding highlights the need for postlicensure surveillance 
of the vaccinated population.
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